HSBC Holdings’s TG Therapeutics TGTX Stock Holding History

HSBC Holdings’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,000	Closed	-$89.8K	–	3156
2024 Q2	$89.8K	Buy	+5,000	New	+$79.8K	﹤0.01%	2750
2024 Q1	–	Sell	-1,000	Closed	-$17.1K	–	3233
2023 Q4	$17.1K	Buy	+1,000	New	+$11.6K	﹤0.01%	2687
2023 Q3	–	Sell	-3,500	Closed	-$84.4K	–	2848
2023 Q2	$84.4K	Buy	+3,500	New	+$90.4K	﹤0.01%	2458
2021 Q2	–	Sell	-4,000	Closed	-$193K	–	3081
2021 Q1	$193K	Buy	+4,000	New	+$192K	﹤0.01%	2555
2020 Q4	–	Sell	-3,000	Closed	-$80K	–	3144
2020 Q3	$80K	Sell	3,000 -7,000	-70%	-$161K	﹤0.01%	2649
2020 Q2	$195K	Buy	+10,000	New	+$161K	﹤0.01%	2379
2019 Q3	–	Sell	-6,000	Closed	-$52K	–	3154
2019 Q2	$52K	Buy	6,000 +4,000	+200%	+$30.2K	﹤0.01%	2655
2019 Q1	$16K	Buy	+2,000	New	+$10.8K	﹤0.01%	2682

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HSBC Holdings's TGTX Position: Q2 2026 in Review

HSBC Holdings reduced its TG Therapeutics (TGTX) stake by 85% in Q2 2026, selling an estimated $3.71M and leaving 15,791 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

HSBC Holdings first reported a position in TGTX in Q2 2018 and has held it in 18 quarters since. The position peaked at $4.37M in Q4 2025. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

HSBC Holdings held 15,791 shares of TG Therapeutics worth $884K as of Q2 2026.
HSBC Holdings sold 90,553 TG Therapeutics shares in Q2 2026, an estimated $3.71M.
TG Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2015 holding.
HSBC Holdings first reported a position in TG Therapeutics in Q2 2018 and has held it in 18 quarters since.
HSBC Holdings's TG Therapeutics position peaked at $4.37M in Q4 2025.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.